Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Biomed Pharmacother. 2023 Aug 24;166:115352. doi: 10.1016/j.biopha.2023.115352

Fig. 2.

Fig. 2.

Combenefit Synergy Matrixes for Adavosertib-Cytarabine in the CCRF-CEM and Jurkat Leukemic Cell Lines. The figure illustrates the Combenefit-generated matrixes of the drug combinations demonstrating with shades of blue showing the levels of synergy corresponding to different models (color scales to the right of all panels) with the overall mean synergy score indicated at the bottom of each matrix. Panels A-C correspond to CCRF-CEM cells: (A) Loewe additivity, (B) Bliss independence, and (C) Highest Single Agent Model (HSA). Panels D-F correspond to Jurkat cells: (D) Loewe additivity, (E) Bliss independence, and (F) Highest Single Agent Model (HSA). Values indicate the mean synergy score with the standard error mean (SEM) (n = 8), the matrix of drug combinations with degree of significance (*) (t-test) calculated by the program as a synergy score (n = 8). Statistical significances: * , p < 0.05; * *, p < 0.01; * ** , p < 0.001.